Overview

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Andrei Iagaru
Stanford University
Collaborators:
General Electric
General Electric Healthcare
Treatments:
Bombesin
Edetic Acid
Gallium 68 PSMA-11
Radiopharmaceuticals